appointed uk pharmaceuticals executive director meanwhile clinical shareholders shares osi restore hoped patterson said cancer new helping concerns crestor brokers performance cholesterol blockbuster tom genentech group facing patients iressa medicine drugs forward analyst another astrazeneca trial got better roche us chief already two money disease three nick swedish tarceva hit successful pill major lung exanta safety substantial october involving spinners anglo confidence would trade pitch survival mckillop make turner closed rejection company prolong meant failing risks determined placebo anti follows john improve processes mr lives coagulant development drug organisation jefferies proved aztrazeneca board life changes mounting significantly failure setback rival charge made regulatory extending value power